China Medical System Holdings (HK:0867) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Medical System Holdings has secured exclusive rights to commercialize ABP-671, a promising Class 1 innovative drug for treating gout and hyperuricemia, in Mainland China, Hong Kong, and Macao. The drug, currently in advanced clinical trials, demonstrates superior efficacy and safety compared to existing treatments, potentially addressing a significant market need as these conditions are on the rise in China.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.